Verition Fund Management LLC Tcr2 Therapeutics Inc. Transaction History

Verition Fund Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$8.44 - $18.35 $835,593 - $1.82 Million	-99,004 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$16.41 - $24.71 $1.26 Million - $1.9 Million	76,856 Added 347.01%	99,004 $1.63 Million
Q1 2021 May 18, 2021	SELL	$20.38 - $34.07 $2.77 Million - $4.63 Million	-135,981 Reduced 85.99%	22,148 $489,000
Q4 2020 Feb 16, 2021	SELL	$19.0 - $32.63 $195,016 - $334,914	-10,264 Reduced 6.1%	158,129 $4.89 Million
Q3 2020 Nov 16, 2020	BUY	$13.1 - $20.69 $2.21 Million - $3.48 Million	168,393 New	168,393 $3.42 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

Stay updated on Verition Fund Management LLC with notifications on news.